Opthea (OPT) Stock Price, News & Analysis

Company Overview

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Key Stats

• Today's Range: $3.23 to $3.53
• 50-Day Range: $3.13 to $5.08
• 52-Week Range: $1.79 to $5.45
• Volume: 15,196 shs
• Average Volume: 24,097 shs
• Market Capitalization: $195.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Strong Buy

Opthea Stock Analysis - MarketRank™

Opthea scored higher than 52% of companies evaluated by MarketBeat, and ranked 603rd out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

Opthea has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Opthea has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Opthea are expected to grow in the coming year, from ($1.39) to ($0.67) per share.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.12% of the outstanding shares of Opthea have been sold short.

Short Interest Ratio / Days to Cover

Opthea has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Opthea has recently increased by 9.60%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Opthea does not currently pay a dividend.

Dividend Growth

Opthea does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.12% of the outstanding shares of Opthea have been sold short.

Short Interest Ratio / Days to Cover

Opthea has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Opthea has recently increased by 9.60%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.24

News Sentiment

Opthea has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Opthea this week, compared to 1 article on an average week.

Search Interest

3 people have searched for OPT on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Opthea insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.20% of the stock of Opthea is held by insiders.

Percentage Held by Institutions

55.95% of the stock of Opthea is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

OPT Stock Analysis - Frequently Asked Questions

How have OPT shares performed this year?

Opthea's stock was trading at $2.95 at the start of the year. Since then, OPT shares have increased by 13.2% and is now trading at $3.34.
View the best growth stocks for 2024 here.

When did Opthea IPO?

Opthea (OPT) raised $161 million in an initial public offering (IPO) on Friday, October 16th 2020. The company issued 9,300,000 shares at $17.26 per share. Citigroup and SVB Leerink served as the underwriters for the IPO and Oppenheimer & Co. and Truist Securities were co-managers.

Who are Opthea's major shareholders?

Opthea's top institutional shareholders include Jane Street Group LLC (0.05%) and Twin Lakes Capital Management LLC (0.03%).

How do I buy shares of Opthea?

Shares of OPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Opthea own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Opthea investors own include PayPal (PYPL), Sunrun (RUN), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), QUALCOMM (QCOM), Ross Stores (ROST) and Zendesk (ZEN).

Company Calendar

• Today: 12/21/2024
• Fiscal Year End: 6/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:OPT
• CUSIP: N/A
• CIK: 1815620
• Web: www.opthea.com
• Phone: 61-3-9826-0399
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $12.00
• High Stock Price Target: $12.00
• Low Stock Price Target: $12.00
• Potential Upside/Downside: +259.3%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.94
• Quick Ratio: 2.94

Sales & Book Value

• Annual Sales: $124,666.00
• Price / Sales: 1,564.49
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.30) per share
• Price / Book: -2.57

Miscellaneous

• Outstanding Shares: 58,395,000
• Free Float: 56,526,000
• Market Cap: $195.04 million
• Optionable: Not Optionable
• Beta: 1.07